Skip to main content

Lantern Pharma Inc.

LTRN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001763950

No open-market purchases or sales by Lantern Pharma Inc. insiders were filed in the last 90 days; 39 institutions reported holding it in 13F filings for Q2 2026, worth $12.0M in total; no superinvestor holds it.

Holders of 5% or more of LTRN

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Lantern Pharma Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Lantern Pharma Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

3 Schedule 13D and 13G filings on Lantern Pharma Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on LTRN
Filed (ET)FilerFormStakeChangeEvent dateFiling
May 15, 20264:20 PM ETBios Equity Partners, LPand 13 others13D/A4.48%571.3K shares−4.10 ppfrom 8.58%Below 5%May 15, 2026SEC
Feb 23, 20264:37 PM ETBios Equity Partners, LPand 13 others13D/A8.58%960.0K shares−1.40 ppfrom 9.98%Feb 20, 2026SEC
Jun 13, 20257:43 PM ETBios Equity Partners, LPand 13 others13D/A9.98%1.08M shares–Jun 12, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Lantern Pharma Inc. shares.

No Form 144 notices for Lantern Pharma Inc. are on file.